CCP
RARE icon

Cardan Capital Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Cardan Capital Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-38,551
Closed -$4.39M – 280
2021
Q1 		$4.39M Buy
+38,551
New +$5.25M 0.53% 60

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Cardan Capital Partners's RARE Position: Q2 2021 in Review

Cardan Capital Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2021, closing a stake of 38,551 shares — an estimated $4.39M sold.

Cardan Capital Partners first reported a position in RARE in Q1 2021 and held it in 1 quarter. The position peaked at $4.39M in Q1 2021. 242 funds tracked by Wall St. Rank hold RARE as of Q2 2021.

  • Cardan Capital Partners reported no remaining Ultragenyx Pharmaceutical position as of Q2 2021 after selling out during the quarter.
  • Cardan Capital Partners sold 38,551 Ultragenyx Pharmaceutical shares in Q2 2021, an estimated $4.39M.
  • Cardan Capital Partners first reported a position in Ultragenyx Pharmaceutical in Q1 2021 and held it in 1 quarter.
  • Cardan Capital Partners's Ultragenyx Pharmaceutical position peaked at $4.39M in Q1 2021.
  • 242 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2021.

Based on Cardan Capital Partners's 13F filing for Q2 2021, filed 20 Jul 2021.